DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for myoclonus-dystonia syndrome — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyoclonus-dystonia syndrome maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myoclonus-dystonia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel alpha subunit 9 (SCN9A) — SCN9A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7W9K · 2.2 Å · ligand O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine (P5S). Experimental structure, not a prediction.
What the evidence adds up to
Myoclonus-dystonia syndrome is linked to mutations in the epsilon-sarcoglycan gene (SGCE) in most families, but in a 2002 study of two families where DRD2 and DYT1 mutations were found, an SGCE mutation was also present in both. A 2006 study of 31 Dutch patients with the myoclonus-dystonia phenotype found that only seven carried an SGCE mutation, meaning the majority tested negative. Positive family history and truncal myoclonus were independent predictors of mutation status, and early disease onset, onset with both myoclonus and dystonia, and axial dystonia were significantly more common in mutation carriers.
A 2018 review stated that zonisamide is an interesting therapeutic option in myoclonus-dystonia, and that bilateral pallidal stimulation has major and lasting therapeutic effects. A 2015 case report described a patient diagnosed with probable myoclonus-dystonia syndrome who showed marked improvement under levetiracetam treatment. However, a 2009 review noted that therapeutic options remain limited overall, and that exploration of functional neurosurgery may be worthwhile in the future given the debilitating nature of many myoclonic syndromes.
The 2018 review also summarised that accumulating evidence suggests an alteration in cerebello-thalamic pathway function, possibly related to a GABAergic deficit reflecting Purkinje cell dysfunction, and that impaired striatal plasticity and disturbed serotonin homeostasis may also be implicated. The 2022 review noted that with next-generation sequencing, the list of genetic diseases manifesting as combined dystonia with myoclonus continues to expand, and proposed diagnostic algorithms for children and adults.
What is still missing are large, controlled trials of the drugs mentioned (zonisamide, levetiracetam) in defined genetic subgroups, and prospective studies that stratify patients by SGCE mutation status and other genetic findings. The natural history of the condition is still being clarified, and the pathological significance of some genetic variants remains undetermined.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 1983 · 147 citations
Myoclonic dystonia
AbstractWe studied 14 patients who had a combination of idiopathic torsion dystonia and myoclonic jerks. In many cases, the same muscles were involved in both the myoclonus and the dystonia. This made observation of the crucial dystonic postures difficult and led to misdiagnosis of other dyskinesias. The jerks usually were brief (50 to 200 msec) and occurred irregularly, often showing cocontraction in antagonist muscles. Frequently, they were superimposed upon sustained dystonic contractions in the same or distant muscles. We found no time-locked EEG event before the jerks. The myoclonus probably arises from a subcortical focus, and the visible jerks probably are part of the spectrum of involuntary movements that accompany torsion dystonia.
Current Opinion in Neurology · 2018 · 104 citations
Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment
AbstractPURPOSE OF REVIEW: The present study will highlight recent advances in the field of myoclonus-dystonia with a focus on clinical aspects, pathogenesis, and treatment. We will also discuss genetics, classification issues, and diagnostic criteria. RECENT FINDINGS: Myoclonus-dystonia is a clinical syndrome corresponding to the phenotype linked to SGCE, the main causative gene. Childhood-onset myoclonus that predominates over dystonia with prominent upper body involvement, an absence of truncal dystonia, associated anxiety or compulsivity, and a positive family history are helpful diagnostic clues. Recent studies demonstrated that zonisamide is an interesting therapeutic option in myoclonus-dystonia, and that bilateral pallidal stimulation has major and lasting therapeutic effects. Accumulating evidence suggests that an alteration in cerebello-thalamic pathway function may play a prominent role and that this is possibly related to a GABAergic deficit reflecting Purkinje cell dysfunction. Impaired striatal plasticity and disturbed serotonin homeostasis may also be implicated. Newly available cellular and rodent models may further assist in investigating the pathogenesis of this disorder. SUMMARY: Comprehensive analysis of the phenotype and precise classification are important in patients with myoclonus and dystonia to identify homogeneous groups of patients. This is critical to guide tailored therapeutic strategies and promote effective research.
ε‐sarcoglycan mutations found in combination with other dystonia gene mutations
AbstractMyoclonus-dystonia is a movement disorder associated with mutations in the epsilon-sarcoglycan gene (SGCE) in most families and in the DRD2 and DYT1 genes in two single families. In both of the latter families, we also found a mutation of SGCE. The molecular mechanisms through which the detected mutations may contribute to myoclonus-dystonia remain to be determined.
Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia
AbstractThe epsilon-sarcoglycan (SGCE) gene is an important cause of myoclonus-dystonia (M-D), although the majority of cases with an M-D phenotype test negative. Seven of 31 patients with the M-D phenotype carried a mutation in the SGCE gene. Positive family history and truncal myoclonus were independent prognostic factors. Early disease onset, onset with both myoclonus and dystonia, and axial dystonia were detected significantly more often in the mutation carriers.
Current Opinion in Neurology · 2009 · 10 citations
Myoclonus
AbstractPURPOSE OF REVIEW: This review examines recent developments in the field of myoclonus. RECENT FINDINGS: The range of clinical features in myoclonic dystonia has been extended and its underlying pathophysiology better defined. The diverse causes leading to jerky tremor and orthostatic myoclonus have been clarified and the need to consider drugs as potential causes highlighted. In patients with combined myoclonus and epilepsy, the major advance has been in our understanding of the natural history of these conditions, which can be more benign than hitherto thought. Finally, the new condition of primary progressive myoclonus of ageing has been identified, although it remains to be seen whether this is a pathological entity or not. SUMMARY: Most progress has been in the characterization of myoclonic syndromes with dystonia and epilepsy. Therapeutic options remain limited, and exploration of the role of functional neurosurgery may be worthwhile in the future, given the debilitating nature of many myoclonic syndromes.
Northern Clinics of Istanbul · 2015 · 8 citations · open access
Myoclonus-dystonia syndrome: case report
AbstractMyoclonus-dystonia syndrome (MDS) is a rare disease manifesting myoclonus as the only neurological symptom which may be accompanied by dystonia. It usually starts in the first or second decade of life. It has a benign course with spontaneous remissions but can cause functional disability in some patients. In this paper, we report a patient diagnosed as probable MDS on the basis of clinical and electrophysiological features who showed marked improvement under levetiracetam treatment.
Annals of Movement Disorders · 2022 · 5 citations · open access
A Clinical Approach to the Patients with Combination of Dystonia and Myoclonus
AbstractMyoclonus–dystonia syndrome is one of the well-defined “combined dystonia” syndromes, now observed in many conditions, including genetic and acquired. With widespread access to next-generation sequencing techniques, the list of genetic diseases manifesting as combined dystonia with myoclonus continues to expand. In this article, we aim to review different etiologies of combined dystonia with myoclonus. We searched databases such as PubMed, OMIM, and Gene Review using the keywords “dystonia and myoclonus” and “myoclonus–dystonia” to identify such disorders. We identified different acquired and genetic disorders manifesting with the combination of dystonia and myoclonus, with or without other movement disorders, irrespective of the predominant movement disorder. In addition, we propose the diagnostic algorithms for children and adults with myoclonus and dystonia, based on clinical manifestations to guide diagnostic procedures and further management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
